LB Pharmaceuticals Inc Common Stock (LBRX) Stock Price
LBRXStock
$36.74+124.02%52W
Market Cap$1.19B
P/E—
PEG Ratio—
Div yield—
Beta1.75
LBRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)28.37%
Price vs S&P 500 (4W)-13.21%
VGM Score90.69
LBRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.80 | -$1.71 | -114.20%(-$0.91) | |
| Q4 2025 | -$0.32 | -$0.45 | -42.10%(-$0.13) | |
| Q3 2025 | -$0.28 | -$0.61 | -117.86%(-$0.33) |
LBRX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.23
4.27
4.27
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | — | — | A | — | — | — | — | $36.74 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders including schizophrenia and bipolar depression. Its lead candidate, LB-102, is a novel benzamide antipsychotic with the potential to be the first of its kind approved in the United States, based on amisulpride, an antipsychotic already approved in over 50 countries.